These 20 cases corresponded to the following genomic categories: TP53 disruption/aneuploidy (n = 6), chromatin/spliceosome mutations (n = 11), and homozygous JAK2 mutation (n = 3), with no case of AML progression recorded in the remaining genomic categories. This evidence concerns the gene JAK2 and acute myeloid leukemia.